You need JavaScript to view this

Treatment of prostate adenocarcinoma permanent implants with I 125: first experience in Uruguay; Tratamiento del adenocarcinoma de prostata con implantes permanentes de I125: primera experiencia en el Uruguay

Abstract

Full text: Objective: To report on the treatment done, toxicity and development of a group of adenocarcinoma patients with localized prostate brachytherapy implants permanent I125. Material and Methods. 37 patients were treated in the period 2001 to 2004 at the Military Hospital Central by this treatment modality. All of them were performed before implantation planning, which consisted of the volumetric calculation and calculation prostate dosimetry that included transrectal prostate ultrasound 3-5 weeks before the procedure. all patients had pathological confirmation of the lesion showed PSA values less than 11 ng / ml and Gleason score less than 7. 70% of patients received neo-adjuvant hormone therapy. In 5 patients an interactive planning system was performed computerized dosimetry, using sequential ultrasound imaging planes, allowed the dosimetric analysis before terminate the procedure and make necessary adjustments if the dose distribution did not conform. This additional dosimetric study we have not been described by other authors. Prescribed in the first 10 patients was dose 144 Gy and 160 Gy in subsequent. All patients underwent post implant CT waffle grid after 15 days of the procedure. analyzed the dose volume histogram (HDV) and D90 values??. Clinical follow-up was performed and PSA biochemical .. Preliminary Results:  More>>
Publication Date:
Dec 15, 2010
Product Type:
Conference
Report Number:
UY-GEO-593
Resource Relation:
Conference: 8. Uruguayan congress of Oncology, 8. Congreso Uruguayo de Oncologia, Montevideo (Uruguay), 2-4 Dec 2004; Other Information: Lecture; Related Information: In: Regional meeting of south Oncologist.Third day of Oncologic nursing| 44 p.
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ADMINISTRATIVE PROCEDURES; ANALGESICS; BIOPSY; BRACHYTHERAPY; CARCINOMAS; CONTROL; DATA; DOSES; DOSIMETRY; GRIDS; HORMONES; IMPLANTS; IODINE 125; PATIENTS; POPULATIONS; PROSTATE; RADIATION DOSE DISTRIBUTIONS; SOCIO-ECONOMIC FACTORS; SURGERY; TOXICITY; URUGUAY
OSTI ID:
22258981
Research Organizations:
Sociedad de Oncologia Medica y Pediatrica del Uruguay, Montevideo (Uruguay)
Country of Origin:
Uruguay
Language:
Spanish
Other Identifying Numbers:
TRN: UY1400102080195
Availability:
Available in abstract form only, full text entered in this record; Available from: http://www.urucan.org.uy/iah/textos/octavo_congreso_oncologia_programa.pdf
Submitting Site:
INIS
Size:
1 page(s)
Announcement Date:
Aug 25, 2014

Citation Formats

Quarneti, A., Clark, O., Glaussius, A., Kaitasoff, P., and Cosia, G. Treatment of prostate adenocarcinoma permanent implants with I 125: first experience in Uruguay; Tratamiento del adenocarcinoma de prostata con implantes permanentes de I125: primera experiencia en el Uruguay. Uruguay: N. p., 2010. Web.
Quarneti, A., Clark, O., Glaussius, A., Kaitasoff, P., & Cosia, G. Treatment of prostate adenocarcinoma permanent implants with I 125: first experience in Uruguay; Tratamiento del adenocarcinoma de prostata con implantes permanentes de I125: primera experiencia en el Uruguay. Uruguay.
Quarneti, A., Clark, O., Glaussius, A., Kaitasoff, P., and Cosia, G. 2010. "Treatment of prostate adenocarcinoma permanent implants with I 125: first experience in Uruguay; Tratamiento del adenocarcinoma de prostata con implantes permanentes de I125: primera experiencia en el Uruguay." Uruguay.
@misc{etde_22258981,
title = {Treatment of prostate adenocarcinoma permanent implants with I 125: first experience in Uruguay; Tratamiento del adenocarcinoma de prostata con implantes permanentes de I125: primera experiencia en el Uruguay}
author = {Quarneti, A., Clark, O., Glaussius, A., Kaitasoff, P., and Cosia, G.}
abstractNote = {Full text: Objective: To report on the treatment done, toxicity and development of a group of adenocarcinoma patients with localized prostate brachytherapy implants permanent I125. Material and Methods. 37 patients were treated in the period 2001 to 2004 at the Military Hospital Central by this treatment modality. All of them were performed before implantation planning, which consisted of the volumetric calculation and calculation prostate dosimetry that included transrectal prostate ultrasound 3-5 weeks before the procedure. all patients had pathological confirmation of the lesion showed PSA values less than 11 ng / ml and Gleason score less than 7. 70% of patients received neo-adjuvant hormone therapy. In 5 patients an interactive planning system was performed computerized dosimetry, using sequential ultrasound imaging planes, allowed the dosimetric analysis before terminate the procedure and make necessary adjustments if the dose distribution did not conform. This additional dosimetric study we have not been described by other authors. Prescribed in the first 10 patients was dose 144 Gy and 160 Gy in subsequent. All patients underwent post implant CT waffle grid after 15 days of the procedure. analyzed the dose volume histogram (HDV) and D90 values??. Clinical follow-up was performed and PSA biochemical .. Preliminary Results: 33 patients were in local control without biochemical failure. Currently 4 patients presented biochemical recurrence with PSA values ??between 4 and 6 ng / ml. In neither disease was found at a distance and then raises confirmation tumor biopsy active presence will undergo surgical treatment protocols localized prostate cancer. HDV values ??D90 and are consistent with the informed by the international literature will be presented. No patient required hospitalization prolonged (greater than 24 hours) or use of higher analgesics. 2 patients had acute urinary retention (G II complication) between the tenth and twentieth day, the rest of the patients had minor complications (G I), hematuria spontaneously fell to fourth day of treatment (1), mild perineal hematoma (1). Most patients dysuria presented from the first week I was treated with alpha-blockers.Conclusions: Prostate brachytherapy with permanent implants is a procedure I125 well tolerated, minimally invasive, Given the short follow-up time of regard them as preliminary results in this selected patient population.}
place = {Uruguay}
year = {2010}
month = {Dec}
}